Tillmann Krahnke

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Richard A. Larson, Brian Druker, François Guilhot et al. · Blood · 2008 · 631 citations · Full text

Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study

Jörge E. Cortes, Michele Baccarani, François Guilhot et al. · Journal of Clinical Oncology · 2009 · 285 citations · Full text

Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

Lydia Roy, Joëlle Guilhot, Tillmann Krahnke et al. · Blood · 2006 · 216 citations

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment

Andreas Hochhaus, Brian Druker, Charles L. Sawyers et al. · Blood · 2007 · 208 citations · Full text

A Single-Dose Comparison of the Acute Effects between the New Somatostatin Analog SOM230 and Octreotide in Acromegalic Patients

Joost van der Hoek, Wouter W. de Herder, Richard A. Feelders et al. · The Journal of Clinical Endocrinology & Metabolism · 2004 · 142 citations · Full text